Search for Tradename: FLOVENT HFA

Summary for Tradename: FLOVENT HFA

Patents:	20
Applicants:	1
NDAs:	1
2009 Sales:	$621,041,000
Therapeutic Class:	Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Respiratory Tract Agents

Latest news for FLOVENT

Cataracts linked to allergy medicine - Tue, 27 Jul 2010 PST

27 July 2010, 3:20 am

Nasal sprays linked to cataracts

26 July 2010, 8:09 pm

Cataracts linked to allergy medicine

25 July 2010, 12:03 am

People's Pharmacy: The link between Flonase and cataracts

24 July 2010, 10:14 pm

Kids with asthma head indoors during smog season

10 July 2010, 2:58 pm

Courtesy of Yahoo News

Glossary

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Delist Req.	Patent Expiration
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	021433	May 14, 2004	RX	Yes	5,658,549*PED	Y	Feb 19, 2015
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	021433	May 14, 2004	RX	Yes	5,674,472*PED	Y	Apr 7, 2015
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	021433	May 14, 2004	RX	Yes	6,161,724*PED	Y	Jul 16, 2018

Export available with Ultimate Plan subscription:

This preview shows a limited data set. Complete access is available with a Subscription

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:
2000 2001 2002 2003 2004
2005 2006 2007 2008 2009

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Follow DrugPatentWatch on Twitter

Bookmark or Share This Page ...